×
About 42,600 results

ALLMedicine™ Non-small Cell Lung Cancer Center

Research & Reviews  14,379 results

Non-Small Cell Lung Cancer (NSCLC)
https://emedicine.medscape.com/article/279960-overview

May 20th, 2022 - Practice Essentials Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) (see the image below), and large cell carcinoma. Patient...

Non-Small Cell Lung Cancer (NSCLC)
http://emedicine.medscape.com/article/279960-overview

May 20th, 2022 - Practice Essentials Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) (see the image below), and large cell carcinoma. Patient...

Deconvolution of malignant pleural effusions immune landscape unravels a novel macropha...
https://doi.org/10.1136/jitc-2021-004239
Journal for Immunotherapy of Cancer; Bruschini S, Pallocca M et. al.

May 19th, 2022 - Immune checkpoint inhibitors are still unable to provide clinical benefit to the large majority of non-small cell lung cancer (NSCLC) patients. A deeper characterization of the tumor immune microenvironment (TIME) is expected to shed light on the ...

Detection of MET amplification by droplet digital PCR in peripheral blood samples of no...
https://doi.org/10.1007/s00432-022-04048-4 10.3390/cancers13123096 10.1016/j.ejca.2017.10.016 10.1073/pnas.0710370104 10.3322/caac.21492 10.1200/JCO.19.00033 10.1038/s41379-018-0182-8 10.1038/s43018-020-0043-5 10.1038/ncomms11815 10.1007/s40291-019-00390-5 10.1016/j.ccm.2011.09.001 10.1016/j.jtho.2016.10.014 10.18632/oncotarget.24430 10.1111/bjh.16442 10.1016/j.jtho.2015.09.009 10.1093/annonc/mdy005 10.1038/s41571-020-0377-z 10.1038/s41576-018-0071-5 10.1007/s00292-020-00831-7 10.1016/j.tranon.2020.100977 10.3978/j.issn.2305-5839.2014.08.11 10.3390/cancers6031540 10.1038/bjc.2015.129 10.1111/cas.14153 10.1200/JCO.18.00177 10.1158/1078-0432.CCR-19-0994 10.1158/1078-0432.CCR-18-1542 10.1080/14728222.2021.1925648 10.1016/j.lungcan.2020.08.021 10.1177/1758835919890286 10.1016/j.ctrv.2018.02.006 10.1016/j.jtho.2016.11.2235 10.1038/s41436-019-0545-7 10.1158/0008-5472.CAN-18-1281 10.1016/j.jtho.2016.04.033 10.1007/s40291-017-0278-8 10.1177/1758834011422556 10.1016/j.jtho.2017.09.400 10.21037/tlcr-19-339 10.1001/jamaoncol.2018.2969 10.1016/j.pharmthera.2017.02.003 10.1200/JCO.2017.74.7576 10.1056/NEJMra1703413 10.1158/2159-8290.CD-19-1446 10.3978/j.issn.2218-6751.2015.03.05 10.1200/JCO.2014.60.7317 10.1158/1078-0432.CCR-14-0450 10.1016/s1470-2045(19)30785-5 10.1093/annonc/mdz227 10.1016/j.lungcan.2011.06.004 10.1016/j.cca.2020.07.003 10.1158/1078-0432.CCR-16-1231 10.1158/1078-0432.CCR-15-2061 10.1038/nrm3012 10.21037/tlcr-20-915 10.1056/NEJMoa2002787 10.1200/JCO.2018.77.7326 10.21037/atm-20-2741 10.1007/s10147-020-01702-0 10.1016/j.lungcan.2019.01.009
Journal of Cancer Research and Clinical Oncology; Fan Y, Sun R et. al.

May 19th, 2022 - Mesenchymal-epithelial transition (MET) amplification is one of the mechanisms accounting for the resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in lung cancer patients, as well as the poor prognosis. Fluor...

OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung ca...
https://doi.org/10.1016/j.intimp.2022.108813
International Immunopharmacology; Lao J, Cao C et. al.

May 18th, 2022 - Immune-checkpoint blockade is widely studied for cancer therapy. Although the co-inhibitory receptor Programmed death-1(PD-1) blockade benefits some non-small cell lung cancer (NSCLC) patients, a large portion of NSCLC patients still fail to respo...

see more →

Guidelines  23 results

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628757
Current Oncology (Toronto, Ont.); Cheema PK, Banerji SO et. al.

Dec 14th, 2021 - In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatm...

Definition and assessment of high risk in patients considered for lobectomy for stage I...
https://doi.org/10.1016/j.jtcvs.2021.07.030
The Journal of Thoracic and Cardiovascular Surgery; Pennathur A, Brunelli A et. al.

Oct 31st, 2021 - Lobectomy is a standard treatment for stage I non-small cell lung cancer, but a significant proportion of patients are considered at high risk for complications, including mortality, after lobectomy and might not be candidates. Identifying who is ...

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0013
Journal of the National Comprehensive Cancer Network : JN... Ettinger DS, Wood DE et. al.

Mar 6th, 2021 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targete...

Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHES...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177089
Chest Mazzone PJ, Gould MK et. al.

Apr 27th, 2020 - The risks from potential exposure to coronavirus disease 2019 (COVID-19), and resource reallocation that has occurred to combat the pandemic, have altered the balance of benefits and harms that informed current (pre-COVID-19) guideline recommendat...

A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lun...
https://doi.org/10.2214/AJR.19.21135
AJR. American Journal of Roentgenology; Chen L, Smith DA et. al.

Jul 31st, 2019 - OBJECTIVE. The purpose of this article is to provide an imaging-based guide of the modern genomic classifications and targeted therapies for advanced non-small cell lung cancer (NSCLC) with an emphasis on the relevance of the 2018 American Society...

see more →

Drugs  145 results see all →

Clinicaltrials.gov  1,253 results

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
https://clinicaltrials.gov/ct2/show/NCT02194738

May 13th, 2022 - PRIMARY OBJECTIVES: I. To centrally test resected non-small cell lung cancer (NSCLC) for genetic mutations to facilitate accrual to randomized adjuvant studies. II. To obtain clinically annotated tumor tissue and patient-matched non-malignant deox...

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
https://clinicaltrials.gov/ct2/show/NCT04929041

May 13th, 2022 - PRIMARY OBJECTIVE: I. To assess if stereotactic body radiation therapy (SBRT) improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage non-small cell lung cancer (NSCLC) patients...

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT02133196

May 13th, 2022 - Background: Patients with metastatic non-small cell lung cancer (NSCLC) have few approved therapeutic options and those that exist are of transient benefit. Recent clinical experiences with experimental agents that release checkpoints on the host ...

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
https://clinicaltrials.gov/ct2/show/NCT02759835

May 13th, 2022 - Background: EGFR tyrosine kinase inhibitors (TKI) have significantly improved the response rate (RR) and survival in patients with tumors harboring EGFR-sensitizing mutations. An invariable consequence of treatment with EGFR-TKIs is the developmen...

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study
https://clinicaltrials.gov/ct2/show/NCT04267848

May 13th, 2022 - PRIMARY OBJECTIVE: I. To compare the disease free survival (DFS) between Arm B versus (vs) Arm C in patients with stage IIA-IIIB (T3-4N2) non-small cell lung cancer. SECONDARY OBJECTIVES: I. To compare the overall survival (OS) between the two tre...

see more →

News  1,239 results

Genomic Testing Challenges Persist
https://www.onclive.com/view/genomic-testing-challenges-persist

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors
https://www.onclive.com/view/jdq443-demonstrates-early-efficacy-signals-in-kras-g12c-mutant-solid-tumors

May 2nd, 2022 - The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 (NCT04699188) trial presented at the 2022 AACR Annual Meeting....

Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC
https://www.onclive.com/view/sotorasib-shows-impressive-2-year-os-rate-in-kras-g12c-nsclc

May 2nd, 2022 - Sotorasib (Lumakras) demonstrated an overall survival (OS) rate of 32.5% (95% CI, 25.0%-40.2%) at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC), according to longer follow-up data from the phase 1/2 CodeBreaK 100 tri...

Durvalumab Combinations Push the Response Envelope in Unresectable NSCLC
https://www.medpagetoday.com/hematologyoncology/lungcancer/98513

May 2nd, 2022 - Patients with unresectable stage III non-small cell lung cancer (NSCLC) had a higher response rate and better progression-free survival when novel targeted agents were added to treatment with durvalumab (Imfinzi), a phase II randomized trial showe...

Durvalumab Plus Oleclumab or Monalizumab Induces Increased Response Rates in NSCLC
https://www.onclive.com/view/durvalumab-plus-oleclumab-or-monalizumab-induces-increased-response-rates-in-nsclc

Apr 28th, 2022 - Consolidation therapy with durvalumab (Imfinzi) and either oleclumab or monalizumab showed increased clinical benefits in patients with unresectable stage III non–small cell lung cancer (NSCLC), according to interim data from the phase 2 COAST stu...

see more →

Patient Education  1 results see all →